543-The Landscape of KRAS Inhibitors in Cancer Treatment

Paper Talk · Feb 23, 2026 · 15m

The paper details the evolving therapeutic landscape of targeting the RAS gene family, a critical oncogenic driver found in roughly 20% of human cancers. While long considered undruggable, recent scientific breakthroughs have led to the development of mutation-specific inhibitors like sotorasib and adagrasib, which primarily target the KRAS G12C mutation. The sources explore the complex biochemical structure of RAS proteins as molecular switches and the diverse signaling pathways they control, such as RAF-MEK-ERK. Despite clinical successes, the text highlights the persistence of acquired and…